Castle Biosciences to Present New Data on DecisionDx-Melanoma at EADO and ACMS Meetings

Castle Biosciences announced in a press release that it will present new clinical data on its DecisionDx-Melanoma test at the 22nd European Congress of Dermato-Oncology in Prague and the American College of Mohs Surgery Annual Meeting in Austin. The studies focus on identifying early-stage melanoma patients at greater risk of recurrence and poor outcomes.

At the European Congress of Dermato-Oncology, data from a multi-center cohort of 1,817 patients with stage I to III cutaneous melanoma showed that DecisionDx-Melanoma provides independent prognostic information beyond American Joint Committee on Cancer staging. The test improved five-year recurrence risk prediction when combined with staging and identified biologically high-risk patients within early-stage disease.

At the American College of Mohs Surgery meeting, a population-based study using the Surveillance, Epidemiology and End Results registry found that the test can identify molecularly high-risk T1 melanoma patients with lower five-year melanoma-specific survival. When combined with staging, it identified more patients who died from melanoma than stage III classification alone.

DecisionDx-Melanoma is a gene expression profile test that analyzes tumor biology to provide personalized risk assessments for patients with stage I to III cutaneous melanoma. It has been clinically validated in more than 10,000 samples and ordered over 230,000 times since launch.